These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 32782566)

  • 1. ERK-mediated negative feedback regulation of oncogenic EGFRvIII in glioblastoma cells.
    Haryuni RD; Tanaka T; Zhou Y; Yokoyama S; Sakurai H
    Oncol Lett; 2020 Sep; 20(3):2477-2482. PubMed ID: 32782566
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An EGFR wild type-EGFRvIII-HB-EGF feed-forward loop regulates the activation of EGFRvIII.
    Li L; Chakraborty S; Yang CR; Hatanpaa KJ; Cipher DJ; Puliyappadamba VT; Rehman A; Jiwani AJ; Mickey B; Madden C; Raisanen J; Burma S; Saha D; Wang Z; Pingle SC; Kesari S; Boothman DA; Habib AA
    Oncogene; 2014 Aug; 33(33):4253-64. PubMed ID: 24077285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SHP-2-dependent mitogen-activated protein kinase activation regulates EGFRvIII but not wild-type epidermal growth factor receptor phosphorylation and glioblastoma cell survival.
    Zhan Y; O'Rourke DM
    Cancer Res; 2004 Nov; 64(22):8292-8. PubMed ID: 15548697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aptamer targeting EGFRvIII mutant hampers its constitutive autophosphorylation and affects migration, invasion and proliferation of glioblastoma cells.
    Camorani S; Crescenzi E; Colecchia D; Carpentieri A; Amoresano A; Fedele M; Chiariello M; Cerchia L
    Oncotarget; 2015 Nov; 6(35):37570-87. PubMed ID: 26461476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EGFR wild type antagonizes EGFRvIII-mediated activation of Met in glioblastoma.
    Li L; Puliyappadamba VT; Chakraborty S; Rehman A; Vemireddy V; Saha D; Souza RF; Hatanpaa KJ; Koduru P; Burma S; Boothman DA; Habib AA
    Oncogene; 2015 Jan; 34(1):129-134. PubMed ID: 24362532
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential gene expression analysis reveals generation of an autocrine loop by a mutant epidermal growth factor receptor in glioma cells.
    Ramnarain DB; Park S; Lee DY; Hatanpaa KJ; Scoggin SO; Otu H; Libermann TA; Raisanen JM; Ashfaq R; Wong ET; Wu J; Elliott R; Habib AA
    Cancer Res; 2006 Jan; 66(2):867-74. PubMed ID: 16424019
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In situ analysis of mutant EGFRs prevalent in glioblastoma multiforme reveals aberrant dimerization, activation, and differential response to anti-EGFR targeted therapy.
    Gajadhar AS; Bogdanovic E; Muñoz DM; Guha A
    Mol Cancer Res; 2012 Mar; 10(3):428-40. PubMed ID: 22232519
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme.
    Shinojima N; Tada K; Shiraishi S; Kamiryo T; Kochi M; Nakamura H; Makino K; Saya H; Hirano H; Kuratsu J; Oka K; Ishimaru Y; Ushio Y
    Cancer Res; 2003 Oct; 63(20):6962-70. PubMed ID: 14583498
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Formation of EGFRwt/EGFRvIII homo- and hetero-dimers in glioblastoma cells as detected by single molecule localization microscopy.
    Jahnke K; Struve N; Hofmann D; Gote MJ; Bach M; Kriegs M; Hausmann M
    Nanoscale; 2024 Aug; 16(32):15240-15255. PubMed ID: 39073345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Role of EGFR-Met Interactions in the Pathogenesis of Glioblastoma and Resistance to Treatment.
    Guo G; Narayan RN; Horton L; Patel TR; Habib AA
    Curr Cancer Drug Targets; 2017; 17(3):297-302. PubMed ID: 28004613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ligand-Independent EGFR Signaling.
    Guo G; Gong K; Wohlfeld B; Hatanpaa KJ; Zhao D; Habib AA
    Cancer Res; 2015 Sep; 75(17):3436-41. PubMed ID: 26282175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective coexpression of VEGF receptor 2 in EGFRvIII-positive glioblastoma cells prevents cellular senescence and contributes to their aggressive nature.
    Jones KA; Gilder AS; Lam MS; Du N; Banki MA; Merati A; Pizzo DP; VandenBerg SR; Gonias SL
    Neuro Oncol; 2016 May; 18(5):667-78. PubMed ID: 26420897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiforme.
    Learn CA; Hartzell TL; Wikstrand CJ; Archer GE; Rich JN; Friedman AH; Friedman HS; Bigner DD; Sampson JH
    Clin Cancer Res; 2004 May; 10(9):3216-24. PubMed ID: 15131063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The epidermal growth factor receptor variant III (EGFRvIII): where wild things are altered.
    Gan HK; Cvrljevic AN; Johns TG
    FEBS J; 2013 Nov; 280(21):5350-70. PubMed ID: 23777544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interactions of EGFR and caveolin-1 in human glioblastoma cells: evidence that tyrosine phosphorylation regulates EGFR association with caveolae.
    Abulrob A; Giuseppin S; Andrade MF; McDermid A; Moreno M; Stanimirovic D
    Oncogene; 2004 Sep; 23(41):6967-79. PubMed ID: 15273741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pro-Oxidant Auranofin and Glutathione-Depleting Combination Unveils Synergistic Lethality in Glioblastoma Cells with Aberrant Epidermal Growth Factor Receptor Expression.
    Martinez-Jaramillo E; Jamali F; Abdalbari FH; Abdulkarim B; Jean-Claude BJ; Telleria CM; Sabri S
    Cancers (Basel); 2024 Jun; 16(13):. PubMed ID: 39001381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EGFRvIII-Stat5 Signaling Enhances Glioblastoma Cell Migration and Survival.
    Roos A; Dhruv HD; Peng S; Inge LJ; Tuncali S; Pineda M; Millard N; Mayo Z; Eschbacher JM; Loftus JC; Winkles JA; Tran NL
    Mol Cancer Res; 2018 Jul; 16(7):1185-1195. PubMed ID: 29724813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The EGFR variant III mutant as a target for immunotherapy of glioblastoma multiforme.
    Chistiakov DA; Chekhonin IV; Chekhonin VP
    Eur J Pharmacol; 2017 Sep; 810():70-82. PubMed ID: 28583430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LRIG1 negatively regulates the oncogenic EGF receptor mutant EGFRvIII.
    Stutz MA; Shattuck DL; Laederich MB; Carraway KL; Sweeney C
    Oncogene; 2008 Sep; 27(43):5741-52. PubMed ID: 18542056
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells.
    Vengoji R; Macha MA; Nimmakayala RK; Rachagani S; Siddiqui JA; Mallya K; Gorantla S; Jain M; Ponnusamy MP; Batra SK; Shonka N
    J Exp Clin Cancer Res; 2019 Jun; 38(1):266. PubMed ID: 31215502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.